Table 4.
Association Between Zygosity at HLA Class II Loci and Liver Cirrhosis in the REVEAL-HBV Cohort in Taiwan Among Chronic HBV Carriers With Inadequate Control of HBV Viral Load
| Among Baseline HBV DNA ≥ 10 000 copies/mL and HBV DNA Persistence | |||
|---|---|---|---|
| HLA Zygosity | Liver Cirrhosis (n = 229) | Chronic HBV Carriers Without Liver Cirrhosis (n = 988) | HR Adjusted for Age, Sex, Principal Components, and Viral Load (95% CI)a |
| Class II loci | |||
| Heterozygous at all loci | 119 (52.0) | 522 (52.8) | Ref. |
| Homozygous in at least 1 locus | 110 (48.0) | 466 (47.2) | 1.07 (.82–1.39) |
| Number of homozygous | |||
| 1 | 77 (33.6) | 329 (33.3) | 1.05 (.79–1.40) |
| 2 | 22 (9.6) | 81 (8.2) | 1.08 (.69–1.71) |
| 3 | 11 (4.8) | 56 (5.7) | 1.16 (.62–2.16) |
| P trend | .56 | ||
| HLA-DPB1 | |||
| Heterozygote | 151 (65.9) | 616 (62.3) | Ref. |
| Homozygote | 78 (34.1) | 372 (37.7) | 1.07 (.71–1.23) |
| HLA-DQB1 | |||
| Heterozygote | 179 (78.2) | 810 (82.0) | Ref. |
| Homozygote | 50 (21.8) | 178 (18.0) | 1.27 (.92–1.74) |
| HLA-DRB1 | |||
| Heterozygote | 203 (88.6) | 879 (89.0) | Ref. |
| Homozygote | 26 (11.4) | 109 (11.0) | 1.10 (.73–1.66) |
Data are No. (%).
Abbreviations: CI, confidence interval; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; REVEAL-HBV, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-Hepatitis B Virus study.
aHRs and 95% CIs were estimated from Cox proportional hazards regression models with attained age as the time scale and were adjusted for sex, principal components, and baseline HBV DNA load (in categories, 10 000–99 999, 100 000–999 999, ≥1 000 000 copies/mL). Censored at diagnosis of liver cirrhosis, diagnosis of HCC, death, and end of follow-up (2004), whichever occurred first.